Top Quality Stocks To Invest In 2015

Three out of five Americans in their 30s are at risk of experiencing a decline in their standard of living after they retire. But despite this dire statistic, your retirement preparedness doesn't have to be hopeless. Constructing a great retirement portfolio is actually quite simple.

Getting a head start
Young investors harness the single most desirable trait in the entire investing universe: time. With time on your side, you have wiggle room to make up for any investing mistakes. Also, being young allows you to invest more aggressively than many investors. And investing small amounts of money now will give you significant advantages later in life.

If those reasons aren't enticing enough, consider that between 1926 and 2010, there was not one single rolling 20-year period with negative returns for stocks. Not one.

So let's get started!

Building your portfolio
You can construct a great portfolio using a simple method and several high-quality stocks. Allocate a portion of your portfolio in core stocks, a piece in growth stocks, and a sliver in aggressive stocks. If your risk tolerance is exceptionally high, consider stomaching an extra stock or two in the growth and aggressive piles. Instead, if your risk tolerance is low, add more core stocks and fewer aggressive ones.

Top Quality Stocks To Invest In 2015: Sandstorm Gold Ltd (SAND)

Sandstorm Gold Ltd. (Sandstorm Gold), formerly Sandstorm Resources Ltd., is a gold streaming company. The Company provides financing to gold mining companies that are looking for capital and in return, receives a gold streaming agreement. It is a non-operating gold mining company with seven gold streams in the portfolio, five of which are producing gold. The Company�� projects include the Aurizona Gold project, the Santa Elena project, the Summit Mine project, the Ming Mine project, the Black Fox Mine project, Bracemac-McLeod project and the Bachelor Lake Mine. It holds 17% interest in the mine gold production from Aurizona. Santa Elena Project, in which the Company holds 20% interest. It holds 12% interest in the mine gold production from Black fox mine project. The Summit Mine project, in which it has 50% interest, 25% interest in Ming mine project and 17.5% interest in Bracemac-McLeod project. Advisors' Opinion:

• [By The Investment Doctor]

  Another, less likely possibility to raise equity is through selling a part of the precious metals in a streaming deal. I can imagine Sandstorm Gold (SAND) and Silver Wheaton (SLW) would be very interested in a substantial precious metals streaming agreement. At the current gold and silver prices NGEX wouldn't even have to sell its entire precious metals production under a streaming arrangement.

Top Quality Stocks To Invest In 2015: Genomma Lab Internacional SAB de CV (LABB.MX)

Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Company�� product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. Advisors' Opinion:

• [By Ben Levisohn]

  He then took a deep dive into Genomma Lab�(LABB.MX), a Mexican producer of over-the counter pharmaceuticals, generic drugs, and personal care products. Now, I’m sitting with a Chromebook in a large auditorium, so I hope I’ve captured the essence of his argument.

Hot Gas Utility Companies To Watch In Right Now: Data Call Technologies Inc (DCLT)

Data Call Technologies, Inc. (Data Call), incorporated on April 4, 2002, focuses is to integrate cutting-edge information/content delivery solutions deployed by the media. The Company's software and services put its clients in control of real-time, news, and other content, including emergency alerts, displayed within one building as well as to thousands of local, regional and national clients, through Digital Signage and Kiosk networks. The Company offers its Direct Lynk Messenger service to customers through the Internet. The Direct Lynk Messenger Service is a Digital Signage product and real-time information service, which provides a range of up-to-date information for display.

Digital Signage is a method advertisers can use to promote, inform, educate, and entertain clients and customers about their businesses and products. Through Digital Signage, companies and businesses can use a single television or a series of networked flat liquid crystal display (LCD) or Plasma screens to market their services and products on site to their clients and customers in real time. Data Call specializes in allows its clients to create their own Digital Signage dynamic content feeds delivered, through Internet, to digital display devices (plasma, LCD, Jumbotron, Kiosks) at their establishments.

The Direct Lynk System allows customers to select from the pre-determined data and information services. The client may choose which individual locations and which displays they would like to receive the Company's feeds based on how their digital signage network is configured.

Advisors' Opinion:

• [By Peter Graham]

  Small cap small cap Internet, app or digital signage stocks Blast Applications, Inc (OTCMKTS: BLAP), TGFIN Holdings Inc (OTCMKTS: TGFN) and Data Call Technologies, Inc (OTCMKTS: DCLT) were getting some extra attention last week. Specifically, two of these stocks have been the subject of paid promotions while the third surged 114.29% on Friday. With that in mind, here is a closer look along with a reality check on all three small cap stocks:

Top Quality Stocks To Invest In 2015: Ultra Clean Holdings Inc.(UCTT)

Ultra Clean Holdings, Inc., together with its subsidiaries, engages in the design, development, engineering, manufacture, and sale of critical modules and subsystems primarily to original equipment manufacturers in semiconductor capital equipment, flat panel, medical, energy, and research industries. It offers gas delivery systems that control the flow, pressure, sequencing, and mixing of specialty gases into and out of the reaction chambers of semiconductor manufacturing tools; chemical mechanical planarization modules; chemical delivery modules, which deliver gases and reactive chemicals from a centralized subsystem to the reaction chamber; and top-plate assemblies that form the top portion of the reaction chamber. The company also provides frame assemblies that form the support structure to which other assemblies are attached and include pneumatic harnesses and cables that connect other critical subsystems together; process modules, which are subsystems of semiconductor manufacturing tools that process integrated circuits onto wafers; and other high level assemblies for use in semiconductor manufacturing, research, flat panel, energy, and medical equipment industries. It sells its products through its direct sales force primarily in North America, Asia, and Europe. Ultra Clean Holding, Inc. was founded in 1991 and is headquartered in Hayward, California.

Advisors' Opinion:

• [By John Kell]

  Ultra Clean Holdings Inc.(UCTT) swung to a fourth-quarter profit as the company recorded a surge in revenue. The company also issued a rosy first-quarter outlook, pushing shares up 17% to $13.94 premarket.

Top Quality Stocks To Invest In 2015: Gilead Sciences Inc.(GILD)

Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Atripla, Truvada, Viread, Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amphotericin B liposome injection to treat invasive fungal infections; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa for the treatment of chronic angina; Vistide, an antiviral medication for the treatment of cytomegalovirus retinitis in patients with AIDS; and Cayston, an inhaled antibiotic used as a treatment to enhance respiratory systems. The company?s products also comprise Tamiflu, an oral antiviral for the treatment and prevention of influenza A and B; Macugen, an intravitreal injection for the treatment of neovascular a ge-related macular degeneration; and Lexiscan/Rapiscan, an injection used as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. Its products under the Phase III clinical trials consist of Cobicistat, a pharmacoenhancer that is under evaluation as a boosting agent for HIV medicines; Elvitegravir, an oral integrase inhibitor being evaluated as part of combination therapy for HIV; Integrase Single-Tablet, a ?Quad? regimen of elvitegravir, cobicistat, tenofovir disoproxil fumarate, and emtricitabine for the treatment of HIV/AIDS in treatment-naive patients; and Aztreonam for inhalation solution for the treatment of cystic fibrosis patients with Pseudomonas aeruginosa. The company?s Phase II clinical trials products comprise Cicletanine, Ranolazine, and Aztreonam, as well as GS 9190, GS 9256, and GS 9451. Its Phase I clinical trial products include GS 7340, GS 5885, GS 6620, GS 9620, and GS 6624. The company was founded in 1987 and is headquartered in Fost er City, California.

Advisors' Opinion:

• [By Ben Levisohn]

  Shares of Celgene gained 0.6% to $142.06 today, even as Amgen (AMGN) dropped 2% to 111.41, Biogen (BIIB) fell 3.1% to $285.81 and the SPDR S&P Biotech ETF (XBI) declined 3.9% to $124.37, extending its losing streak to three days. Gilead Sciences (GILD) dipped 0.2% to $73.90, ending a nine-day winning streak

• [By Bryan Murphy]

  When investors think of non-Hodgkin's lymphoma stocks, big names like Gilead Sciences, Inc. (NASDAQ:GILD) and Celgene Corporation (NASDAQ:CELG) come to mind. Both GILD and CELG are making prolific progress in the war on NHL, and both are fine, well-positioned companies. It's little Infinity Pharmaceuticals Inc. (NASDAQ:INFI) that may end up making the proverbial quantum leap in the non-Hodgkin's lymphoma stocks arena, however, and better still, it's INFI shares that may well end up doling out a much bigger reward than Gilead or Celgene could to newcomers.

• [By Brian Orelli]

  Dark horse
  Gilead Sciences (NASDAQ: GILD  ) , the final name mentioned by the insiders, has been slowly building out its oncology franchise through multiple acquisitions and even an academic partnership.

• [By Ben Levisohn]

  No, says Credit Suisse analyst Ravi Mehrotra and team, when contemplating the recent drops in Gilead Sciences (GILD), Biogen Idec (BIIB),�Celgene (CELG) and their ilk. They explain why: